文献速递肿瘤 PET/CT核素与放射性配体治疗

PSMA PET/CT引导的挽救性选择性淋巴结放疗治疗前列腺癌根治术后淋巴结转移:双中心长期结局分析

PSMA PET/CT-guided salvage elective nodal radiotherapy for nodal metastases after radical prostatectomy: a bi-institutional long-term outcome analysis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-09-04

本研究回顾性分析了179例在前列腺癌根治术后出现淋巴结复发并接受PSMA PET/CT引导的挽救性选择性淋巴结放疗(ENRT)的患者,中位随访60.3个月。在真正生化复发患者中,5年无转移生存率(MFS)为74.3%,生化无进展生存率(BPFS)为62.3%;同期使用ADT与更好的MFS和BPFS相关,而术后PSA持续与更差结局相关。

要点

  • PSMA PET/CT引导的挽救性ENRT在真实临床实践中提供持久的长期疾病控制。
  • 真正生化复发患者5年MFS为74.3%,接近前瞻性试验报告的结果。
  • 同期ADT与改善的MFS和BPFS相关,术后PSA持续与更差结局相关。

核心结论

  • PSMA PET/CT引导的挽救性ENRT主要联合ADT在常规临床实践中为淋巴结复发患者提供持久的长期疾病控制。
  • 在根治术后真正复发患者中,5年MFS率为74.3%,接近前瞻性试验报告的结果。
  • 缺乏系统收集的临床医生评估毒性和患者报告结局,无法可靠评估治疗耐受性。

研究设计与样本

  • 回顾性分析两个三级中心2014年至2024年间179例接受PSMA PET/CT引导的ENRT治疗的前列腺癌根治术后淋巴结复发患者。
  • 纳入盆腔和/或腹主动脉旁淋巴结转移患者,主要终点为无转移生存率(MFS),次要终点包括生化无进展生存率(BPFS)和总生存率(OS)。
  • 采用Kaplan-Meier法估计生存结局,Cox回归分析评估预后因素。

主要发现

  • 179例患者中,104例(58.1%)为根治术后真正生化复发,75例(41.9%)为PSA持续。
  • 中位随访60.3个月后,真正生化复发患者5年MFS和BPFS分别为74.3%和62.3%,全体队列分别为61.2%和56.4%。
  • 多变量分析显示,与未使用ADT相比,同期ADT与改善的MFS(HR 0.36,p < 0.001)和BPFS(HR 0.26,p < 0.001)相关。
  • 术后PSA持续与更差结局相关(MFS:HR 2.72,p < 0.001;BPFS:HR 2.09,p = 0.005)。

关键数值与推荐

  • 真正生化复发患者5年MFS率为74.3%,5年BPFS率为62.3%。
  • 全体队列5年MFS率为61.2%,5年BPFS率为56.4%。
  • 同期ADT对比无ADT:MFS的HR为0.36(p < 0.001),BPFS的HR为0.26(p < 0.001)。
  • 术后PSA持续对比无持续:MFS的HR为2.72(p < 0.001),BPFS的HR为2.09(p = 0.005)。

临床怎么用

  • PSMA PET/CT引导的挽救性ENRT可考虑用于根治术后淋巴结复发患者,尤其是真正生化复发者。
  • 同期ADT可能改善接受挽救性ENRT患者的MFS和BPFS。
  • 术后PSA持续患者预后较差,需更密切监测和个体化治疗策略。

局限性

  • 回顾性研究设计。
  • 缺乏系统收集的临床医生评估毒性和患者报告结局,无法可靠评估治疗耐受性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: PSMA PET/CT has transformed the detection of nodal recurrence after radical prostatectomy, yet real-world evidence on long-term outcomes of PSMA PET/CT-guided salvage elective nodal radiotherapy (ENRT) remains limited. This study evaluated oncological outcomes of PSMA PET/CT-guided salvage ENRT in a bi-institutional cohort with extended follow-up. METHODS: We retrospectively analysed 179 patients who received PSMA PET/CT-based ENRT for nodal recurrence after radical prostatectomy at two tertiary centres between 2014 and 2024. Patients with pelvic and/or paraaortic lymph node metastases were included. The primary endpoint was metastasis-free survival (MFS); secondary endpoints included biochemical progression-free survival (BPFS) and overall survival (OS). Survival outcomes were estimated using the Kaplan-Meier method, and prognostic factors were assessed using Cox regression analysis. RESULTS: Of the 179 patients, 104 (58.1%) had true biochemical recurrence after radical prostatectomy, whereas 75 (41.9%) had PSA persistence. After a median follow-up of 60.3 months, 5-year MFS and BPFS rates were 74.3% and 62.3%, respectively, in patients with true biochemical recurrence, compared with 61.2% and 56.4% in the overall cohort. In multivariable analyses of the entire cohort, concomitant ADT was associated with improved MFS (HR 0.36, p < 0.001) and BPFS (HR 0.26, p < 0.001), compared with no ADT. PSA persistence after surgery was associated with worse outcomes (MFS: HR 2.72, p < 0.001; BPFS: HR 2.09, p = 0.005). CONCLUSION: PSMA PET/CT-guided salvage ENRT predominantly combined with ADT provides durable long-term disease control in patients with nodal recurrence in routine clinical practice. In patients with true recurrence after radical prostatectomy, the 5-year MFS rate was 74.3%, approaching outcomes reported in prospective trials. However, the absence of systematically collected clinician-assessed toxicity and patient-reported outcomes precludes a reliable assessment of treatment tolerability.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Vorbach SM, Seppi T, Santo G, et al. PSMA PET/CT-guided salvage elective nodal radiotherapy for nodal metastases after radical prostatectomy: a bi-institutional long-term outcome analysis. Eur J Nucl Med Mol Imaging. 2026. PMID: 42693211. doi:10.1007/s00259-026-08147-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。